Q2 2019 EPS Estimates for MannKind Co. Increased by Zacks Investment Research (MNKD)

MannKind Co. (NASDAQ:MNKD) – Zacks Investment Research increased their Q2 2019 earnings per share estimates for MannKind in a report released on Monday, May 13th. Zacks Investment Research analyst B. Marckx now anticipates that the biopharmaceutical company will post earnings per share of ($0.06) for the quarter, up from their prior estimate of ($0.08). Zacks Investment Research also issued estimates for MannKind’s Q3 2019 earnings at ($0.08) EPS, Q4 2019 earnings at ($0.08) EPS, FY2019 earnings at ($0.31) EPS, FY2020 earnings at ($0.22) EPS and FY2021 earnings at ($0.12) EPS.

A number of other equities research analysts have also recently weighed in on the company. Svb Leerink initiated coverage on MannKind in a research note on Friday, February 22nd. They issued an “outperform” rating and a $3.00 price objective for the company. Leerink Swann initiated coverage on MannKind in a research note on Friday, February 22nd. They issued an “outperform” rating and a $3.00 price objective for the company. BidaskClub upgraded MannKind from a “hold” rating to a “buy” rating in a research note on Thursday, March 14th. BTIG Research initiated coverage on MannKind in a research note on Tuesday. They issued a “buy” rating and a $3.00 price objective for the company. Finally, HC Wainwright reduced their price objective on MannKind from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $2.85.

Shares of NASDAQ MNKD opened at $1.32 on Thursday. MannKind has a twelve month low of $0.94 and a twelve month high of $3.04. The company has a market capitalization of $247.87 million, a price-to-earnings ratio of -2.24 and a beta of 2.56.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.02. The firm had revenue of $17.45 million during the quarter, compared to analysts’ expectations of $18.03 million. During the same quarter in the prior year, the firm posted ($0.25) EPS.

Several institutional investors have recently added to or reduced their stakes in MNKD. BlueCrest Capital Management Ltd acquired a new stake in shares of MannKind during the first quarter valued at $38,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of MannKind by 12.7% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 75,586 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 8,507 shares during the last quarter. Morgan Stanley boosted its stake in shares of MannKind by 182.8% during the first quarter. Morgan Stanley now owns 2,508,114 shares of the biopharmaceutical company’s stock valued at $4,941,000 after acquiring an additional 1,621,199 shares during the last quarter. MetLife Investment Advisors LLC acquired a new stake in shares of MannKind during the first quarter valued at $162,000. Finally, SEI Investments Co acquired a new stake in shares of MannKind during the first quarter valued at $58,000. Institutional investors and hedge funds own 30.26% of the company’s stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States.

Featured Article: Roth IRA

Earnings History and Estimates for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.